Synageva, Mitsubishi extend deal on protein drugs for rare disease

04/4/2012 | Genetic Engineering & Biotechnology News

Mitsubishi Tanabe Pharma and Synageva BioPharma will jointly develop a second therapeutic protein for an orphan disease using the latter's protein expression platform as part of their expanded rare-disease deal. Synageva will receive $9 million in upfront fees and reimbursement for development costs, plus potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care